Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)

This study has been completed.
Astellas Pharma US, Inc.
Information provided by:
Gilead Sciences Identifier:
First received: September 13, 2005
Last updated: November 24, 2009
Last verified: November 2009

Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. The investigational drug, regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist, the receptor responsible for coronary vasodilation, and is being studied for potential use as a pharmacologic stress agent in myocardial perfusion imaging (MPI) studies. This study will compare the safety and efficacy of regadenoson to that of Adenoscan in detecting reversible myocardial perfusion defects.

Condition Intervention Phase
Coronary Artery Disease
Drug: Regadenoson
Drug: Adenosine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: A Phase III, Randomized, Double-Blind Study of Intravenous CVT-3146 Versus Adenoscan® in Patients Undergoing Stress Myocardial Perfusion Imaging

Resource links provided by NLM:

Further study details as provided by Gilead Sciences:

Primary Outcome Measures:
  • Non-inferiority of regadenoson to Adenoscan for use in SPECT myocardial perfusion imaging in assessing reversible perfusion defects [ Time Frame: After radiopharmaceutical administration ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety and tolerability comparison of regadenoson to Adenoscan [ Time Frame: Up to two weeks ] [ Designated as safety issue: Yes ]
  • Additional comparisons of images obtained with regadenoson to those obtained with Adenoscan [ Time Frame: After radiopharmaceutical administration ] [ Designated as safety issue: No ]

Enrollment: 787
Study Start Date: April 2004
Study Completion Date: June 2005
Primary Completion Date: June 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: Regadenoson
0.4 mg, bolus intravenous injection
Other Names:
  • Lexiscan
  • CVT-3146
Active Comparator: 2
Drug: Adenosine
0.14 mg/kg/min for 6 minutes, intravenous infusion
Other Name: Adenoscan

Detailed Description:

ADVANCE MPI 2 is a multi-national, double-blind, randomized, active-controlled, parallel group clinical trial to evaluate the safety and efficacy of regadenoson in SPECT MPI compared to that of the approved pharmacological stress agent, Adenoscan. Patients referred for a clinically indicated pharmacological stress MPI study will be eligible for enrollment. The trial is designed: (1) to compare the pharmacological stress SPECT images obtained with regadenoson to those obtained with Adenoscan, and (2) to compare the safety and tolerability of the two stress agents.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Referred for a clinically indicated pharmacological stress SPECT myocardial perfusion imaging study

Exclusion Criteria:

  • Any condition precluding the safe administration of Adenoscan for a SPECT myocardial perfusion imaging study
  • Pregnant or breast-feeding, or (if pre-menopausal), not practicing acceptable method of birth control
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00208312

United States, California
Multiple study locations (see Central Contact); CV Therapeutics, Inc.
Palo Alto, California, United States, 94304
Sponsors and Collaborators
Gilead Sciences
Astellas Pharma US, Inc.
  More Information

Additional Information:
Responsible Party: Philip Sager, Vice President, Clinical Research, Gilead Sciences Identifier: NCT00208312     History of Changes
Other Study ID Numbers: CVT 5132
Study First Received: September 13, 2005
Last Updated: November 24, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Gilead Sciences:
SPECT Myocardial Perfusion Imaging
Reversible Perfusion Defect

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Arterial Occlusive Diseases
Cardiovascular Diseases
Heart Diseases
Vascular Diseases
Adenosine A2 Receptor Agonists
Anti-Arrhythmia Agents
Cardiovascular Agents
Central Nervous System Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Purinergic Agents
Purinergic Agonists
Purinergic P1 Receptor Agonists
Sensory System Agents
Therapeutic Uses
Vasodilator Agents processed this record on November 27, 2014